Cytosorbents Corporation (CTSO)
CTSO Stock Price Chart
Explore Cytosorbents Corporation interactive price chart. Choose custom timeframes to analyze CTSO price movements and trends.
CTSO Company Profile
Discover essential business fundamentals and corporate details for Cytosorbents Corporation (CTSO) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Devices
IPO Date
8 Aug 2006
Employees
149.00
Website
https://www.cytosorbents.comCEO
Phillip P. Chan
Description
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications of cardiopulmonary bypass surgery, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from fresh whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove toxic chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.
CTSO Financial Timeline
Browse a chronological timeline of Cytosorbents Corporation corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 3 Nov 2026
Upcoming earnings on 10 Aug 2026
Upcoming earnings on 5 May 2026
Upcoming earnings on 1 Jan 2026
Upcoming earnings on 6 Nov 2025
EPS estimate is -$0.06, while revenue estimate is $10.02M.
Earnings released on 7 Aug 2025
EPS came in at -$0.05 surpassing the estimated -$0.07 by +28.57%, while revenue for the quarter reached $9.62M , beating expectations by +4.29%.
Earnings released on 14 May 2025
EPS came in at -$0.06 surpassing the estimated -$0.08 by +25.00%, while revenue for the quarter reached $8.73M , missing expectations by -3.11%.
Earnings released on 31 Mar 2025
EPS came in at -$0.03 surpassing the estimated -$0.07 by +57.14%, while revenue for the quarter reached $6.52M , missing expectations by -35.33%.
Earnings released on 7 Nov 2024
EPS came in at -$0.08 falling short of the estimated -$0.07 by -14.29%, while revenue for the quarter reached $8.61M , missing expectations by -8.89%.
Earnings released on 13 Aug 2024
EPS came in at -$0.08 surpassing the estimated -$0.09 by +11.11%, while revenue for the quarter reached $9.89M , beating expectations by +2.22%.
Earnings released on 9 May 2024
EPS came in at -$0.12 matching the estimated -$0.12, while revenue for the quarter reached $9.79M , beating expectations by +0.06%.
Earnings released on 14 Mar 2024
EPS came in at -$0.12 surpassing the estimated -$0.14 by +14.29%, while revenue for the quarter reached $8.67M , missing expectations by -6.59%.
Earnings released on 9 Nov 2023
EPS came in at -$0.21 falling short of the estimated -$0.12 by -75.00%, while revenue for the quarter reached $7.75M , missing expectations by -17.77%.
Earnings released on 1 Aug 2023
EPS came in at -$0.14 falling short of the estimated -$0.11 by -27.27%, while revenue for the quarter reached $8.07M , missing expectations by -26.81%.
Earnings released on 2 May 2023
EPS came in at -$0.17 falling short of the estimated -$0.13 by -30.77%, while revenue for the quarter reached $7.91M , missing expectations by -9.39%.
Earnings released on 9 Mar 2023
EPS came in at -$0.01 surpassing the estimated -$0.17 by +94.12%, while revenue for the quarter reached $7.64M , missing expectations by -12.36%.
Earnings released on 3 Nov 2022
EPS came in at -$0.28 falling short of the estimated -$0.16 by -75.00%, while revenue for the quarter reached $6.46M , missing expectations by -27.94%.
Earnings released on 2 Aug 2022
EPS came in at -$0.25 falling short of the estimated -$0.14 by -78.57%, while revenue for the quarter reached $7.33M , missing expectations by -23.44%.
Earnings released on 3 May 2022
EPS came in at -$0.21 falling short of the estimated -$0.15 by -40.00%, while revenue for the quarter reached $7.92M , missing expectations by -18.47%.
Earnings released on 8 Mar 2022
EPS came in at -$0.21 falling short of the estimated -$0.13 by -61.54%, while revenue for the quarter reached $9.70M , beating expectations by +0.17%.
Earnings released on 4 Nov 2021
EPS came in at -$0.15 falling short of the estimated -$0.12 by -25.00%, while revenue for the quarter reached $8.90M , missing expectations by -25.57%.
Earnings released on 3 Aug 2021
EPS came in at -$0.11 falling short of the estimated -$0.04 by -181.04%, while revenue for the quarter reached $11.37M , missing expectations by -7.37%.
Earnings released on 4 May 2021
EPS came in at -$0.10 falling short of the estimated -$0.03 by -200.03%, while revenue for the quarter reached $10.14M , missing expectations by -28.22%.
Earnings released on 9 Mar 2021
EPS came in at -$0.02 falling short of the estimated -$0.01 by -99.88%, while revenue for the quarter reached $11.53M .
Earnings released on 4 Nov 2020
EPS came in at -$0.02 surpassing the estimated -$0.09 by +77.78%, while revenue for the quarter reached $10.25M , missing expectations by -78.41%.
CTSO Stock Performance
Access detailed CTSO performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.